Investigation of molecular alterations of AKT-3 in triple-negative breast cancer

Histopathology

Volumn 64, Issue 5, 2014, Pages 660-670

  O'Hurley, Gillian ^a   Daly, Etáin ^b   O'Grady, Anthony ^b   Cummins, Robert ^b   Quinn, Cecily ^c   Flanagan, Louise ^c   Pierce, Aisling ^c   Fan, Yue ^c   Lynn, Miriam A ^a   Rafferty, Máirín ^a   Fitzgerald, Dara ^a   Pontén, Fredrik ^d   Duffy, Michael J ^c   Jirström, Karin ^e   Kay, Elaine W ^b   Gallagher, William M ^c  

^a ONCOMARK LIMITED   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d UPPSALA UNIVERSITY   (Sweden)

^e LUND UNIVERSITY   (Sweden)

Author keywords

AKT 3; ER positive breast cancer; Fluorescence in situ hybridization; Molecular alterations; Triple negative breast cancer

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN AKT 3; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; AKT3 PROTEIN, HUMAN; PROTEIN KINASE B; TUMOR MARKER;

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY;

BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896125528     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12313     Document Type: Article

References (26)

1. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin. Breast Cancer 2009; 9(Suppl. 2); S73-S81.
2. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control 2010; 17; 173-176.
3. Tryfonopoulos D, Walsh S, Collins DM et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann. Oncol. 2011; 22; 2234-2240.
4. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010; 16; 53-61.
5. Liu W, Bagaitkar J, Watabe K. Roles of akt signal in breast cancer. Front. Biosci. 2007; 12; 4011-4019.
6. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: action on multiple fronts. Trends Biochem. Sci. 2004; 29; 233-242.
7. Zinda MJ, Johnson MA, Paul JD et al. Akt-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin. Cancer Res. 2001; 7; 2475-2479.
8. Kada F, Saji M, Ringel MD. Akt: a potential target for thyroid cancer therapy. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2004; 4; 181-185.
9. Tokunaga E, Kimura Y, Mashino K et al. Activation of PI3k/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006; 13; 137-144.
10. Klos KS, Zhou X, Lee S et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003; 98; 1377-1385.
11. Kirkegaard T, Witton CJ, Edwards J et al. Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. Histopathology 2010; 56; 203-211.
12. Hill MM, Hemmings BA. Inhibition of protein kinase B/Akt. Implications for cancer therapy. Pharmacol. Ther. 2002; 93; 243-251.
13. Thompson JE, Thompson CB. Putting the rap on Akt. J. Clin. Oncol. 2004; 22; 4217-4226.
14. Irie HY, Pearline RV, Grueneberg D et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol. 2005; 171; 1023-1034.
15. Stal O, Perez-Tenorio G, Akerberg L et al. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res. 2003; 5; R37-R44.
16. Nakatani K, Thompson DA, Barthel A et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 1999; 274; 21528-21532.
17. O'Brien SL, Fagan A, Fox EJ et al. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int. J. Cancer 2007; 120; 1434-1443.
18. Walsh S, Flanagan L, Quinn C et al. mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors. Breast 2012; 21; 178-182.
19. Yeh IT, Martin MA, Robetorye RS et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod. Pathol. 2009; 22; 1169-1175.
20. Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: where are we? Int. J. Cancer 2012; 131; 2471-2477.
21. Koboldt DC, Fulton RS, McLellan MD et al. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490; 61-70.
22. Winston JS, Ramanaryanan J, Levine E. HER-2/neu evaluation in breast cancer: are we there yet? Am. J. Clin. Pathol. 2004; 121(Suppl.); S33-S49.
23. Ried T, Just KE, Holtgreve-Grez H et al. Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res. 1995; 55; 5415-5423.
24. Rosenberg CL. Polysomy 17 and HER-2 amplification: true, true, and unrelated. J. Clin. Oncol. 2008; 26; 4856-4858.
25. Banerji S, Cibulskis K, Rangel-Escareno C et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486; 405-409.
26. Salido M, Pijuan L, Martinez-Aviles L et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J. Thorac. Oncol. 2011; 6; 21-27.